Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CB03-154 adjunctive therapy in adult focal epilepsy
ChiCTR2600116929Phase 2Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CB03-154 in Focal Onset Epilepsy (4 arms), sponsored by Huashan Hospital. Primary endpoints: Median percent change in monthly focal seizure frequency and Severity and incidence of related adverse events and serious adverse events. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
CB03-154
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on ChiCTR2600116929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116929.